Abstract 4363027: Paradoxical Renal Protection after Euglycemic DKA in a CKD Stage 4 Diabetic Patient on Empagliflozin: A Case Report and Mechanistic Insights
Abstract
Introduction:
Over the last few years, studies have demonstrated that the usage of SGLT2 inhibitors in patients with diabetes mellitus and chronic kidney disease has significantly reduced the risk of hospitalisation for heart failure, progression to kidney failure, and all-cause mortality. Notably, a clinical trial evaluating the usage of empagliflozin in CKD revealed that cardiorenal protective effects persisted up to a year after cessation. However, SGLT2 inhibitors have also been associated with an increased incidence of euglycemic diabetic ketoacidosis (euDKA), a condition characterised by normoglycemia, metabolic acidosis, and ketosis. This case highlights an unexpected renal benefit following euDKA in a patient with advanced chronic kidney disease (CKD) on empagliflozin.
Case Description:
A 58-year-old female with type 2 diabetes (HbA1c 7.8%), CKD stage 4 (eGFR 23 mL/min/1.73msq.), and HFpEF presented with fatigue, nausea, and tachypnea. Blood glucose was 140 mg/dL. She was on empagliflozin (10 mg/day) for cardiorenal protection. Lab results confirmed euDKA (pH 7.18, ketones 4.8 mmol/L, bicarbonate 12 mEq/L), triggered by influenza A and reduced intake. Notably, serum creatinine improved from 2.4 to 2.1 mg/dL during hospitalisation. She was treated with IV insulin, dextrose, and empagliflozin was held. Eight weeks post-discharge, the drug was restarted after stable labs and patient education. Over 12 months, eGFR remained stable (22–25), and there were no further DKA…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.